Drugs / SQIN-Furosemide
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05419115 | Nov 2022 → Mar 2026 | heart failure | NHS Greater Glasgow and Clyde | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SQIN-Furosemide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05419115 ↗ |
| Known as | furosemide | “The investigational furosemide formulation (SQIN-Furosemide) is a Captisol®buffered solution of 80mg furosemide in 2.7 mL (30 mg/mL) at pH 7.4 (range: 7.0 to 7.8).” NCT05419115 ↗ |
| Route | Subcutaneous | “SC infusion will be performed using the SQIN-Infusor” NCT05419115 ↗ |